North America Fibromyalgia Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Anticonvulsants, Antidepressants, Muscle Relaxants and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The North America Fibromyalgia Treatment Market would witness market growth of 3.7% CAGR during the forecast period (2023-2030).
The complexity of fibromyalgia is the reason why diagnosis and treatment are required to take a multifaceted approach, combining medical practitioners from different specialties to address the disease's many symptoms and comorbidities. In addition to several drugs, it may also be treated with dietary and lifestyle changes. The symptoms of fibromyalgia include extreme pain, difficulty sleeping, tiredness, irritability, and memory loss. Fibromyalgia is commonly accompanied by several other symptoms as well. Only three drugs have been approved for use, particularly in treating fibromyalgia, at this time.
Because of this, products that are off-label are utilized more frequently. But increased research and development in pain management is anticipated to support using approved medications for the illness indication. The burden of chronic pain is mostly to blame for the market's expansion. Researchers have found that fibromyalgia changes how the brain and spinal cord process painful and non-painful signals, increasing the intensity of painful sensations. The increased incidence of chronic pain conditions like fibromyalgia is anticipated to increase demand for different treatment alternatives, ultimately fueling market expansion during the anticipated period.
Mexico's road traffic fatalities have remained consistently high in recent years, despite the country's population of nearly 130 million people. There were over 16,000 recorded deaths in 2019. Due to a lack of accountability among various sectors and institutions, Mexico's federal government struggled to achieve intersectoral coordination and progress in road safety, resulting in fatal and non-fatal traffic injuries. The increasing number of road accidents in the region will create growth opportunities for the market as FM can occur to people involved in road accidents, thereby boosting the market expansion in the region.
The US market dominated the North America Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,022.1 million by 2030. The Canada market is poised to grow at a CAGR of 6.1% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 5.1% during (2023 - 2030).
Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments covered in the Report:
By Drug Class
- Anticonvulsants
- Antidepressants
- Muscle Relaxants
- Others
- Drug stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
- US
- Canada
- Mexico
- Rest of North America
- AbbVie, Inc.
- Novartis AG
- Eli Lilly And Company
- Amneal Pharmaceuticals, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Zydus Lifesciences Ltd.
- Lupin Limited
- Abbott Laboratories
- Viatris, Inc.
- Sun Pharmaceutical Industries Ltd.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Fibromyalgia Treatment Market, by Drug Class
- 1.4.2 North America Fibromyalgia Treatment Market, by Distribution Channel
- 1.4.3 North America Fibromyalgia Treatment Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition & scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. North America Fibromyalgia Treatment Market by Drug Class
- 3.1 North America Anticonvulsants Market by Country
- 3.2 North America Antidepressants Market by Country
- 3.3 North America Muscle Relaxants Market by Country
- 3.4 North America Others Market by Country
- Chapter 4. North America Fibromyalgia Treatment Market by Distribution Channel
- 4.1 North America Drug stores & Retail Pharmacies Market by Country
- 4.2 North America Hospital Pharmacies Market by Country
- 4.3 North America Online Providers Market by Country
- Chapter 5. North America Fibromyalgia Treatment Market by Country
- 5.1 US Fibromyalgia Treatment Market
- 5.1.1 US Fibromyalgia Treatment Market by Drug Class
- 5.1.2 US Fibromyalgia Treatment Market by Distribution Channel
- 5.2 Canada Fibromyalgia Treatment Market
- 5.2.1 Canada Fibromyalgia Treatment Market by Drug Class
- 5.2.2 Canada Fibromyalgia Treatment Market by Distribution Channel
- 5.3 Mexico Fibromyalgia Treatment Market
- 5.3.1 Mexico Fibromyalgia Treatment Market by Drug Class
- 5.3.2 Mexico Fibromyalgia Treatment Market by Distribution Channel
- 5.4 Rest of North America Fibromyalgia Treatment Market
- 5.4.1 Rest of North America Fibromyalgia Treatment Market by Drug Class
- 5.4.2 Rest of North America Fibromyalgia Treatment Market by Distribution Channel
- Chapter 6. Company Profiles
- 6.1 Abbott Laboratories
- 6.1.1 Company Overview
- 6.1.2 Financial Analysis
- 6.1.3 Segmental and Regional Analysis
- 6.1.4 Research & Development Expense
- 6.1.5 SWOT Analysis
- 6.2 AbbVie, Inc.
- 6.2.1 Company Overview
- 6.2.2 Financial Analysis
- 6.2.3 Regional Analysis
- 6.2.4 Research & Development Expense
- 6.2.5 Recent strategies and developments:
- 6.2.5.1 Acquisition and Mergers:
- 6.3 Novartis AG
- 6.3.1 Company Overview
- 6.3.2 Financial Analysis
- 6.3.3 Segmental and Regional Analysis
- 6.3.4 Research & Development Expense
- 6.3.5 Recent strategies and developments:
- 6.3.5.1 Acquisition and Mergers:
- 6.4 Eli Lilly And Company
- 6.4.1 Company Overview
- 6.4.2 Financial Analysis
- 6.4.3 Regional Analysis
- 6.4.4 Research & Development Expenses
- 6.5 Amneal Pharmaceuticals, Inc.
- 6.5.1 Company Overview
- 6.5.2 Financial Analysis
- 6.5.3 Segmental Analysis
- 6.5.4 Research & Development Expenses
- 6.6 Teva Pharmaceutical Industries Ltd.
- 6.6.1 Company Overview
- 6.6.2 Financial Analysis
- 6.6.3 Regional Analysis
- 6.6.4 Research & Development Expenses
- 6.7 Zydus Lifesciences Ltd.
- 6.7.1 Company Overview
- 6.7.2 Financial Analysis
- 6.7.3 Segmental and Regional Analysis
- 6.7.4 Research & Development Expense
- 6.7.5 Recent strategies and developments:
- 6.7.5.1 Trials and Approvals:
- 6.8 Lupin Limited
- 6.8.1 Company Overview
- 6.8.2 Financial Analysis
- 6.8.3 Recent strategies and developments:
- 6.8.3.1 Trials and Approvals:
- 6.9 Viatris, Inc.
- 6.9.1 Company Overview
- 6.9.2 Financial Analysis
- 6.9.3 Segmental Analysis
- 6.9.4 Research & Development Expense
- 6.10. Sun Pharmaceutical Industries Ltd.
- 6.10.1 Company Overview
- 6.10.2 Financial Analysis
- 6.10.3 Regional Analysis
- 6.10.4 Research & Development Expenses
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook